WEBULL
WebtradeDownload

How Investors May Respond To LeMaitre Vascular (LMAT) Trimmed 2026 Outlook Despite Higher Q2 Sales

Simply Wall St · 2d ago
  • LeMaitre Vascular, Inc. recently reported second-quarter 2026 results, with sales rising to US$70.38 million and net income to US$17.05 million, alongside confirming a US$0.25 quarterly dividend and updated earnings guidance for the remainder of 2026.
  • Behind the headline growth, the company cited currency headwinds, Middle East export delays, and cardiac allograft supply constraints as reasons for missing prior guidance and trimming its full-year revenue outlook.
  • Next, we’ll examine how the guidance reduction amid currency and supply challenges may reshape LeMaitre Vascular’s investment narrative.

AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

LeMaitre Vascular Investment Narrative Recap

To own LeMaitre Vascular, you need to believe its niche vascular focus and growing international footprint can keep driving steady revenue and earnings progress despite operational friction. The latest results reinforce that picture of growth, but also highlight how FX headwinds, Middle East export delays, and cardiac allograft supply constraints remain the key near term swing factors. The guidance cut looks incremental rather than thesis breaking, but it does put these execution and supply risks more clearly in focus.

Among the recent announcements, the updated 2026 guidance is most relevant here. Management now expects full year sales of about US$274.3 million to US$278.3 million and EPS of US$2.84 to US$2.94, a modest trim from earlier targets that reflects the FX, export, and tissue supply issues surfacing in Q2. For investors focused on catalysts like international Artegraft expansion and margin resilience, this reset sets a more measured near term bar for operational delivery.

However, against the growth story, the ongoing cardiac allograft supply constraints are an issue investors should be aware of, because...

Read the full narrative on LeMaitre Vascular (it's free!)

LeMaitre Vascular's narrative projects $340.6 million revenue and $84.0 million earnings by 2029. This requires 9.1% yearly revenue growth and a roughly $18.3 million earnings increase from $65.7 million today.

Uncover how LeMaitre Vascular's forecasts yield a $110.00 fair value, a 34% upside to its current price.

Exploring Other Perspectives

LMAT 1-Year Stock Price Chart
LMAT 1-Year Stock Price Chart

Some of the lowest estimates were already assuming revenue of about US$336.5 million and earnings of roughly US$81.3 million by 2029, so if you worry that prolonged allograft bottlenecks and higher logistics costs will bite harder than expected, you might see the new guidance as a step toward that more cautious view.

Explore 4 other fair value estimates on LeMaitre Vascular - why the stock might be worth as much as 51% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your LeMaitre Vascular research is our analysis highlighting 3 key rewards that could impact your investment decision.
  • Our free LeMaitre Vascular research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LeMaitre Vascular's overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.